The MedicalXpress report on the Nature Communications RCT (n=108 adults with HIV lipohypertrophy, 32 weeks, semaglutide vs placebo) correctly highlights DunedinPACE slowing and multi-organ clock improvements, yet underplays key constraints. This double-blind trial demonstrates reduced chronic immune activation and visceral fat as primary drivers, aligning with broader GLP-1 mechanisms seen in cardiovascular outcome trials like SELECT. However, the 9% DunedinPACE effect and PCGrimAge mortality-risk signal must be viewed against the modest sample and HIV-specific accelerated aging baseline; general-population extrapolation remains speculative. Cross-referencing the linked npj Aging pilot (n unspecified, 24 weeks, MASLD subgroup) shows 42% of participants with DunedinPACE reversal tied to liver-fat loss, plus telomere lengthening in 49%, yet both studies share the same UCSD group, raising potential confirmation bias absent independent replication. A 2024 Lancet Diabetes & Endocrinology review of GLP-1 pleiotropy notes consistent anti-inflammatory effects across 50+ trials but flags absent long-term epigenetic data outside HIV. Missed by coverage: no adjustment for lifestyle confounders or direct comparison to metformin aging trials (e.g., TAME pilot). Overall RCT quality is high for internal validity yet low for external aging claims until larger, diverse cohorts confirm results.